doi: 10.3389/fphar.2024.1332147 Received 02 November 2023 Accepted 15 March 2024 Published 02 April 2024 Volume 15 - 2024 Edited by Elham Rahme, McGill University, Canada Reviewed by Mario Enrico Canonico, University of Colorado, United States Claudiu Morgovan, Lucian Blaga University of Sibiu, Romania Updates Copyright 2024 Coumau, Gaspar, Terrier, Schulthess-Lisibach, Lutters, Le Pogam and Csajka
While the trial failed to demonstrate a significant slowing in disease progression with either dose, the findings suggested that a subgroup of patients with early ALS and moderate disease progression could potentially benefit from the higher dose
Unlike Zostavax [17] , which is given as a single shot, Shingrix [18] is given as two identical intramuscular doses, two to six months apart
Who May Benefit AOD-9604 for joint health may be worth discussing with a physician if you: Experience joint pain or stiffness related to cartilage wear or early-stage osteoarthritis Are an active individual dealing with repetitive joint stress from exercise or physical work Want to support joint health proactively as part of an aging wellness strategy Have joint concerns alongside metabolic health goals (AOD-9604 can address both) Haven't achieved satisfactory results with conventional joint health approaches Are looking for joint support options that don't carry the gastrointestinal risks of long-term NSAID use AOD-9604 isn't a substitute for surgical intervention in cases of severe joint damage, and it shouldn't be used as a replacement for physical therapy or appropriate rehabilitation protocols
Available at: 208 WibowoC
Other people never had a clear early rash, so the picture stays fuzzy
